Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

2023-509179-18-00 Protocol C2321001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 13 Aug 2019 · Status Ongoing, recruiting · 3 EU/EEA countries · 26 sites · Protocol C2321001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 270
Countries 3
Sites 26

Castration Resistant Prostate Cancer (CRPC)

Key facts

Sponsor
Pfizer Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
13 Aug 2019 → ongoing
Decision date (initial)
2024-09-13
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-509179-18-00
EudraCT number
2018-001835-37
ClinicalTrials.gov
NCT03460977

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Castration Resistant Prostate Cancer (CRPC)

VersionLevelCodeTermSystem organ class
24.0 LLT 10080213 In situ follicular lymphoma 10029104
21.0 LLT 10012820 Diffuse large B-cell lymphoma NOS 10029104
21.1 LLT 10076506 Castration-resistant prostate cancer 10029104
21.1 LLT 10041071 Small cell lung cancer stage unspecified 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pfizer Inc.

Sponsor organisation
Pfizer Inc.
Address
66 Hudson Boulevard East
City
New York
Postcode
10001-2189
Country
United States

Scientific contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Public contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Locations

3 EU/EEA countries · 26 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 4 4
Poland Ongoing, recruiting 12 6
Spain Ongoing, recruiting 90 16
Rest of world
Russian Federation, China, Japan, Korea, Republic of, United States
164

Investigational sites

Bulgaria

4 sites · Ended
Complex Oncology Center Vratsa EOOD
Department of Medical Oncology, Bulevard Vtori Yuni 68, 3000, Vratsa
Specialized Hospital For Active Treatment Of Oncology Haskovo EOOD
Department of Medical Oncology, Bulevard Siedinenie 49, 6304, Haskovo
Complex Oncological Center Plovdiv EOOD
Department of Medical Oncology and Oncological Diseases in Gastroenterology, Bulevard Aleksandir Stamboliyski 2a, 4004, Plovdiv
Complex Oncology Center Ruse EOOD
Department of Medical Oncology, 2 Nezavisimost street, 7000, Ruse

Poland

6 sites · Ongoing, recruiting
Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie
N/A, Ul. Tytusa Chalubinskiego 7, 75-581, Koszalin
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
N/A, Ul. Wilhelma Konrada Roentgena 5, 02-781, Warsaw
Lux Med Onkologia Sp. z o.o.
N/A, Ul. Szamocka 6, 01-748, Warsaw
Centrum Medyczne Medyk Sp. z o.o.
N/A, Al. Tadeusza Rejtana 53, 35-326, Rzeszow
Jagiellonskie Centrum Innowacji Sp. z o.o.
N/A, Ul. Profesora Michala Bobrzynskiego 14, 30-348, Cracow
In Vivo Sp. z o.o.
N/A, Ul. Kaszubska 17h, 85-048, Bydgoszcz

Spain

16 sites · Ongoing, recruiting
Hospital De La Santa Creu I Sant Pau
Hematology, Carrer De San Quinti 89, 08041, Barcelona
Hospital Universitari Vall D Hebron
N/A, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Y Politecnico La Fe
N/A, Avenida De Fernando Abril Martorell 106, 46026, Valencia
Hospital Clinic De Barcelona
N/A, Calle Villarroel 170, 08036, Barcelona
Hospital Hm Nou Delfos
N/A, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
N/A, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Quironsalud Barcelona
N/A, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario 12 De Octubre
N/A, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitario Hm Sanchinarro
N/A, Calle Ona 10, 28050, Madrid
Hospital Universitario Quironsalud Madrid
NEXT Madrid Phase I trials, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Institut Catala D'oncologia
N/A, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Consorcio Hospitalario Provincial De Castellon
N/A, Avinguda Del Doctor Clara 19, 12006, Castello De La Plana
Hospital Universitario Ramon Y Cajal
N/A, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitario Virgen De La Victoria
N/A, Calle Del Arroyo Teatinos Sn, 29010, Malaga
Hospital Clinico Universitario De Valencia
Hematology and Medical Oncology Service, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Clinico San Carlos
Oncology Service, Calle Del Profesor Martin Lagos Sn, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2023-07-20 2024-07-04 2024-06-27
Poland 2023-05-16 2023-05-16
Spain 2019-08-13 2019-10-08

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-07 Spain Acceptable with conditions
2024-08-28
2024-08-28
2 SUBSTANTIAL MODIFICATION SM-1 2024-10-23 Spain Acceptable with conditions 2024-11-18
3 SUBSTANTIAL MODIFICATION SM-2 2025-03-05 Spain Acceptable
2025-06-09
2025-06-13
4 SUBSTANTIAL MODIFICATION SM-3 2025-06-25 Spain Acceptable
2025-09-01
2025-09-03
5 SUBSTANTIAL MODIFICATION SM-4 2025-09-09 Spain Acceptable 2025-10-09
6 SUBSTANTIAL MODIFICATION SM-5 2025-11-19 Spain Acceptable
2026-02-19
2026-02-22